文献速递炎症性肠病

乌帕替尼在溃疡性结肠炎进阶治疗中治疗失败风险最低:真实世界行政索赔研究

Upadacitinib Is Associated With the Lowest Risk of Treatment Failure Among Advanced Therapies for Ulcerative Colitis: A Real-World Administrative Claims Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-09-29

基于美国OptumLabs行政索赔数据库,纳入7283例溃疡性结肠炎患者共9078次进阶治疗启动,比较六种进阶治疗的真实世界有效性。经倾向评分逆概率加权后,乌帕替尼相比英夫利西单抗、阿达木单抗、维得利珠单抗、乌司奴单抗和托法替尼均与显著更低的治疗失败风险相关,且无激素疾病稳定季度比例最高。

要点

  • 乌帕替尼治疗失败风险显著低于英夫利西单抗、阿达木单抗、维得利珠单抗、乌司奴单抗和托法替尼。
  • 维得利珠单抗治疗失败风险低于英夫利西单抗和阿达木单抗。
  • 乌帕替尼调整后无激素疾病稳定季度比例最高,为0.70(95%CI 0.63-0.77)。

核心结论

  • 在大型真实世界溃疡性结肠炎队列中,乌帕替尼与所有其他评估的进阶治疗相比治疗失败风险最低、无激素疾病稳定比例最高。

研究设计与样本

  • 使用美国全国代表性行政索赔数据库OptumLabs Data Warehouse,识别2016至2023年间启动英夫利西单抗、阿达木单抗、维得利珠单抗、乌司奴单抗、托法替尼或乌帕替尼的溃疡性结肠炎患者。
  • 共纳入7283例患者,贡献9078次治疗启动:英夫利西单抗n=1624、阿达木单抗n=2315、维得利珠单抗n=3164、乌司奴单抗n=1274、托法替尼n=547、乌帕替尼n=154。
  • 主要结局为至治疗失败时间(复合终点:指数日期后>90天发生的炎症性肠病相关住院、炎症性肠病相关手术或新皮质类固醇处方),治疗停药和换药作为删失事件。
  • 采用基于多项倾向评分的逆概率加权(广义提升模型)和死亡竞争风险调整控制混杂。

主要发现

  • 经逆概率加权调整后,乌帕替尼相比英夫利西单抗治疗失败风险显著更低(HR 0.61;95%CI 0.42-0.88)。
  • 乌帕替尼相比阿达木单抗治疗失败风险显著更低(HR 0.59;95%CI 0.41-0.86)。
  • 乌帕替尼相比维得利珠单抗治疗失败风险显著更低(HR 0.69;95%CI 0.48-1.00)。
  • 乌帕替尼相比乌司奴单抗治疗失败风险显著更低(HR 0.65;95%CI 0.45-0.95)。
  • 乌帕替尼相比托法替尼治疗失败风险显著更低(HR 0.59;95%CI 0.40-0.88)。

临床怎么用

  • 在溃疡性结肠炎进阶治疗选择中,乌帕替尼与最低的治疗失败风险和最高的无激素疾病稳定比例相关,尤其适用于关注快速控制与减少激素暴露的患者。
  • 维得利珠单抗相对于抗TNF药物(英夫利西单抗、阿达木单抗)与更低的治疗失败风险相关,可作为进阶治疗的参考选项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We compared the real-world effectiveness of advanced therapies (ATs) in patients with ulcerative colitis (UC). METHODS: Using the OptumLabs Data Warehouse, a nationally representative United States administrative claims database, we identified patients with UC initiating infliximab, adalimumab, vedolizumab, ustekinumab, tofacitinib, or upadacitinib between 2016 and 2023. The primary outcome was time to treatment failure (composite of inflammatory bowel disease-related hospitalization, inflammatory bowel disease-related surgery, or new corticosteroid prescription occurring >90 days after index date); treatment discontinuation and switching were treated as censoring events. The secondary outcome was the proportion of quarters in corticosteroid-free disease stability. Confounding was addressed using multinomial propensity score-based inverse probability weighting with generalized boosted models and competing risk adjustment for mortality. RESULTS: We identified 7283 patients contributing 9078 treatment episodes with initiation of infliximab (n = 1624), adalimumab (n = 2315), vedolizumab (n = 3164), ustekinumab (n = 1274), tofacitinib (n = 547), or upadacitinib (n = 154). After inverse probability weighting adjustment, upadacitinib was associated with significantly lower risk of treatment failure compared with infliximab (hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.42-0.88]), adalimumab (HR, 0.59; 95% CI, 0.41-0.86), vedolizumab (HR, 0.69; 95% CI, 0.48-1.00), ustekinumab (HR, 0.65; 95% CI, 0.45-0.95), and tofacitinib (HR, 0.59; 95% CI, 0.40-0.88). Vedolizumab was associated with lower risk of treatment failure compared with infliximab (HR, 0.88; 95% CI, 0.79-0.98) and adalimumab (HR, 0.86; 95% CI, 0.78-0.95). Upadacitinib had the highest adjusted proportion of quarters in corticosteroid-free disease stability (0.70; 95% CI, 0.63-0.77). The findings were consistent in patients with and without prior AT exposure. CONCLUSIONS: In this large real-world UC cohort, upadacitinib was associated with the lowest risk of treatment failure and greatest corticosteroid-free disease stability compared with all other ATs evaluated.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Hupé M, Ahuja D, Yeh KH, et al. Upadacitinib Is Associated With the Lowest Risk of Treatment Failure Among Advanced Therapies for Ulcerative Colitis: A Real-World Administrative Claims Study. Clin Gastroenterol Hepatol. 2026. PMID: 42810421. doi:10.1016/j.cgh.2026.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。